1. The prophylaxis and treatment potential of supplements for COVID-19
- Author
-
Amirhosein Khoshi, Masoud Khataminia, Fatemeh Saghafi, Hassan Rezai Ghaleno, Razieh Avan, Solomon Habtemariam, Mohammadreza Safdari, Seyed Mohammad Nabavi, and Adeleh Sahebnasagh
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Pneumonia, Viral ,Disease ,medicine.disease_cause ,Adjuvant therapy ,Antioxidants ,03 medical and health sciences ,0302 clinical medicine ,Full Length Article ,medicine ,Animals ,Humans ,Supplements ,Intensive care medicine ,Pandemics ,Coronavirus ,Pharmacology ,business.industry ,COVID-19 ,Vitamins ,medicine.disease ,Clinical trial ,Pneumonia ,030104 developmental biology ,Dietary Supplements ,Coronavirus Infections ,Cytokine storm ,business ,030217 neurology & neurosurgery - Abstract
The global impact of the new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), infection that caused COVID-19 has been evident in the last few months from the unprecedented socioeconomic disruption to more than 600,000 deaths. The lack of vaccine and effective therapeutic agents for the disease prompted world-wide effort to test those antiviral therapeutics already in use for other diseases. Another interesting approach has been based on the pathological sequel of the disease that involve severe inflammatory reaction (or the cytokine storm) associated with pneumonia in critically ill patients. This article outlines the prophylaxis therapeutic potential of supplements vitamins and micronutrients in COVID-19. By ameliorating the inflammatory and oxidative stress associated with the disease and some direct antiviral effects, the application of these agents as adjuvants and other alternative approaches are discussed. Available clinical trials including those currently registered on these supplements are scrutinized.
- Published
- 2020